# Tirzepatide Dosage Calculator | BAC Water & Dose Titration

## Tirzepatide (Mounjaro / Zepbound) Dosing

Tirzepatide is the weekly dual-hormone injection sold as Mounjaro for type 2 diabetes and Zepbound for obesity. The top dose produced 20.9% average weight loss over 72 weeks and 20.2% in a direct comparison with semaglutide's 13.7%.¹ ²

Its second receptor, GIP, separates tirzepatide from approved single-receptor GLP-1 drugs and helps explain the larger population-level weight loss.⁷ ¹⁷

That 20.9% came from participants averaging about 105 kg at a BMI of 38, most of whom were sedentary. A lighter or leaner body receives more exposure per kilogram and may show a different balance of appetite, heart-rate, and lean-mass effects. The cohort defines what the average can and cannot predict.

Tirzepatide has three different dose floors. The label starts at 2.5 mg weekly, long-duration obesity evidence starts at 5 mg, and registered human activity has been measured as low as 1 mg in an early diabetes study.¹ ²¹ Each number answers a different question.

Obesity trials use weight as the primary endpoint. Diabetes trials use blood-sugar control, where tirzepatide's GIP-driven improvement in insulin sensitivity is most visible.⁷ ¹³ Results from one population do not transfer cleanly to the other.

Abdomen, thigh, and upper-arm injections produce similar exposure. In the checked trial protocol, participants self-injected into the abdomen or thigh; the upper arm required a caregiver.⁸

## Dosing **Tirzepatide** · At a Glance

Every dose is weekly. What separates the rungs is not cadence but the evidence standing behind each one, read low to high.

| Weekly dose | What it anchors | Evidence boundary |
| --- | --- | --- |
| 1 mg | Lowest measured human dose | Diabetes dose-ranging activity, not obesity proof.²¹ |
| 0.5–2 mg | Microdose band | Extrapolation from the 1 mg anchor, PK, and mechanism.²¹ |
| 2.5 mg | Label starter, held 4 weeks | Adaptation dose, not the obesity-trial floor |
| 5 mg | First obesity-trial dose | Lowest 72-week non-diabetic obesity arm.¹ |
| 5–10 mg | Maintenance band | Continuation strong; a 112-week trial found that a 5 mg step-down held most loss.¹² |
| 10 mg | Most result for least burden | Captures most of the 15 mg mean weight loss.¹ |
| 15 mg | Trial and label ceiling | Do not exceed the tested ceiling |

## How Tirzepatide's Two Signals Work

Natural GLP-1 and GIP fire briefly after a meal and clear within minutes. Tirzepatide holds both signals on for a week, allowing the drug to reach appetite centers and metabolic tissues that a short meal signal barely reaches.⁷

The two signals are not balanced. Tirzepatide engages GIP near the strength of the natural hormone but activates GLP-1 about 18 times more weakly than natural GLP-1.⁷ After accounting for protein binding in blood, the drug is roughly 20-fold GIP-forward and has no meaningful glucagon activity.

<!-- chart:tirz-receptor-ladder -->

GIP engagement runs ahead at every dose and reaches roughly 50% occupancy by 15 mg. GLP-1 engagement stays lower but continues climbing through the approved range, so each higher step can still change appetite and tolerability. Glucagon remains below 0.3% even at 15 mg, ruling out the glucagon-driven liver and heart effects seen with retatrutide.⁷

### GIPR: the identity receptor

At the 2.5 mg starter dose, GIP receptor occupancy is already about 13%. By 5 mg, the sustained signal approaches the peak produced by a large meal.⁷

In diabetes trials, every dose improved insulin sensitivity while reducing the amount of insulin needed.¹³ GIP also activates an anti-nausea circuit in the brainstem, which helps offset some of the gastrointestinal burden created by GLP-1.⁷

### GLP-1R: appetite, tolerability, and heart rate

The GLP-1 arm carries appetite suppression, slower stomach emptying, most nausea, and part of the heart-rate signal. Occupancy stays low, but each engaged receptor keeps sending its main message longer than it would under a balanced signal (cAMP bias with low receptor internalization).⁷

In a head-to-head trial against liraglutide, tirzepatide reduced measured food intake and craving more despite lower GLP-1 occupancy.¹⁷ The effect lowers the drive to eat rather than increasing restraint.

### GCGR: the negative control

Glucagon is on the chart only to be ruled out. Tirzepatide's glucagon-receptor occupancy stays under 0.3% even at 15 mg.⁷ So its liver-fat reduction, its lipid improvements, and its heart-rate rise do not run through a glucagon arm the way retatrutide's do. They run through weight loss, insulin sensitization, and the GLP-1 arm. When a tirzepatide result points the same direction as a glucagon-drug result, the cause is shared downstream physiology, not a hidden third receptor.

## Reading Each Dose on the Ladder

Trial and clinical protocols seek the lowest dose that keeps the relevant markers moving without unacceptable side effects. Active-loss markers include appetite, weight trend, waist, glucose, blood pressure, and tolerability. Maintenance shifts the focus to weight stability, hunger, strength, and laboratory results.

The 2.5 mg starter already engages GIP. It begins below the obesity-trial floor because appetite and gastrointestinal effects need time to adapt before escalation.⁷ At 5 mg, both GIP and GLP-1 are clinically active.

From 7.5 to 10 mg, GLP-1 engagement roughly doubles from the 5 mg level. Appetite suppression deepens, heart-rate effects become more visible, and gut symptoms can return after each increase.

The 12.5 to 15 mg band adds modestly to average weight loss but widens the high-response tail. It also carries the greatest heart-rate, gastrointestinal, over-loss, and lean-mass burden.⁷

| Weeks | Weekly dose | Practical read |
| --- | --- | --- |
| 1–4 | 2.5 mg | Starter and adaptation dose; real GIP signal, light GLP-1 |
| 5–8 | 5 mg | First long-duration obesity-trial dose.¹ |
| 9–12 | 7.5 mg | Intermediate step when 5 mg is not enough |
| 13–16 | 10 mg | Captures most of the 15 mg mean with less top-dose burden.¹ |
| 17–20 | 12.5 mg | Bridge to ceiling when the response requires it |
| 21+ | 15 mg | Trial and label ceiling |

Tirzepatide has a roughly 5.4-day half-life. Blood levels rise across the first several weekly doses and settle near steady state after about four weeks.⁸ That is why the four-week hold matters: the full effect of a dose change is not visible in the first few days.

## What Tirzepatide Feels Like, Week to Week

The most commonly described early effect is quieter food noise: less background pull toward snacks and less negotiation over each meal. It can change within days. In withdrawal interviews, it was also the first effect participants noticed returning.¹² ²³

### Hunger changes shape, not just size

Physical hunger can remain while craving and anticipation decline. In a head-to-head trial against a full-strength GLP-1 drug, tirzepatide reduced food craving without changing measured restraint.¹⁷ Slower stomach emptying also makes smaller portions feel filling for longer.⁹

People whose eating was driven by stress, reward, or constant mental effort often describe the quiet as relief. Others experience it as a loss of pleasure or mild emotional flatness around food.²³

Trial mood scores moved slightly better rather than worse, so the negative experience appears to be a minority signal that standard adverse-event tables do not capture well.

### The week-to-week arc

The 2.5 mg starter can feel subtle because GLP-1 engagement is still light. After each increase, blood levels peak over 24 to 72 hours, when nausea and fullness are most likely to return.⁸ These effects usually ease during the four-week hold.

At a stable dose, food noise and appetite can partly return as weight loss approaches a plateau. Withdrawal reverses the pattern: food noise was among the first effects participants reported returning.¹²

### The side effects that dominate the lived complaints

Nausea leads the trial tables but clusters during escalation and often fades. Constipation is less dose-dependent and can persist, making it a more durable reason for discontinuation in patient reports.⁸ ²³ Sulfur burps reflect food sitting longer in a slowed stomach.⁹ ²³

Fatigue ranks second only to nausea in patient forums, although much of it tracks the calorie deficit rather than tirzepatide itself.²³ Fried or fatty foods, coffee, meat, and alcohol can also become less appealing.

### The effects that sit outside the trial tables

Menstrual-cycle changes are widely discussed in patient communities, including irregular or doubled cycles during rapid loss.²³ Trials did not pre-specify them, so the adverse-event tables cannot estimate incidence. Emotional flatness has the same evidence gap: it appears in patient reports but was not measured as a dedicated outcome.

### What to do about it

Protein intake and resistance training influence how much lost weight comes from fat versus lean tissue, especially in lower-BMI users. Nausea usually eases with time at a held dose, while persistent constipation often requires separate management.

Fatigue, lightheadedness, and low mood can reflect the calorie deficit rather than the drug itself. Protein, electrolytes, and sleep are the first variables to assess.

## What Different Bodies Do at the Same Dose

The receptor chart does not change by phenotype. What the body does with that same signal changes a great deal. Type 2 diabetes, body weight, sex, baseline fat, and cardiac responsiveness all reshape the output.

<!-- chart:tirz-weight-phenotype -->

Two reads carry the chart. First, diabetes blunts weight loss by roughly 6 to 7 percentage points versus non-diabetic obesity at the same dose, because long-standing high glucose dampens the metabolic cascade the drug works through.⁴ Second, the 10-to-15 mg step keeps adding weight loss in every band. That matters because blood-sugar control does the opposite: HbA1c is nearly maxed out by 10 mg, so the top dose is justified by weight, not by additional glucose lowering.⁵ ¹³

Body size also shifts the felt dose. Because the milligram amount is fixed, a lighter body gets more drug exposure per pound: roughly 22% to 23% more at 70 kg compared with a 90 kg reference. At 120 kg, the published estimates disagree, ranging from 21% to 33% less.⁸

The 0.8 weight exponent used to calculate that shift was fixed as a model assumption rather than fitted from tirzepatide data. The dose still comes from response and tolerability, but a lighter person is running a hotter exposure at the same number on the vial.

### Non-diabetic obese: the loudest instrument

Non-diabetic obesity provides the clearest weight-loss estimate. In a body-composition substudy of participants averaging about 105 kg, roughly 75% of lost weight was fat and 25% was lean; visceral fat fell about 40%.³

After withdrawal, insulin resistance returned in proportion to regained weight.¹² Maintaining some weight loss did not preserve the full metabolic benefit when substantial regain occurred.

### Type 2 diabetes: sensitization, not just weight

Diabetes trials measure a different baseline and endpoint than obesity trials. HbA1c fell about 2.0 to 2.6 percentage points and approached its floor by 10 mg, while weight continued responding to higher doses.⁵ ¹³ Participants starting above 8% HbA1c often fell by more than 3 points; those starting below 8% fell by about 1.5 to 2 points.¹³

Tirzepatide lowers glucose mainly by improving insulin sensitivity rather than forcing the pancreas to release more insulin. In trials that added it to injected insulin, basal insulin requirements fell roughly 60% to 80% while control improved.¹³

Low-blood-sugar risk therefore tracks the insulin or sulfonylurea used alongside tirzepatide more than the tirzepatide dose itself.

Liver fat, visceral fat, and kidney markers move to the center here, and each still reads through its own baseline. Liver fat fell up to 47% at 15 mg in a fatty-liver diabetes substudy, a figure that only lands for someone who has liver fat to lose; a high-cardiovascular-risk kidney cohort showed a slower decline in kidney function and about a third less protein leak, which travels to a similar-risk body, not a healthy one.⁶ ¹⁴

### Lean and metabolically healthy: a safety read, not an efficacy target

No long trial has tested tirzepatide in lean, metabolically healthy people. Exposure per milligram is higher, particularly in lighter East Asian users, while the smaller fat reserve makes a 75:25 fat-to-lean split more consequential.

In one published case, an active, lean-adjacent man lost about one-third of his total weight as muscle on 2.5 mg and recovered it after adding resistance training and increasing protein.¹⁶ This is a cautionary case, not an incidence estimate.

## Heart Rate: The Escalation Peak the Mean Hides

Tirzepatide's heart-rate effect is the most misread number on the drug, because the trials report two different things and people quote them interchangeably.

<!-- chart:tirz-hr-instruments -->

The week-72 steady-state mean in the obese cohort was about +0.6 to +2.6 bpm across doses.¹¹ During escalation around weeks 16 to 20, the peak ran two to three times higher. The chronic average and titration peak describe different phases.

About 10% of tirzepatide participants had a heart-rate increase above 20 bpm during escalation, compared with 3% on placebo.¹¹ A lean Japanese cohort reached +10 to +13 bpm, and 23% of Japanese participants at 15 mg crossed the abnormal-pulse threshold versus 7% of other participants, despite only 17% higher exposure.¹¹

Lean and East Asian bodies showed greater cardiovascular sensitivity than exposure alone predicted. The dedicated cardiovascular trial did not find excess major events. Its all-cause mortality estimate was lower, but that interval was nominal because the trial's testing sequence stopped when superiority on the primary cardiac endpoint was not met. Resting heart rate remains a titration marker rather than a one-time measurement.¹⁴

## How to Titrate, and the Cost of Going Too Fast

The final dose shapes the endpoint, but the length of escalation and the number of steps are the largest measured regimen-level drivers of tolerance.

<!-- chart:tirz-titration-tolerability -->

The early program proved it directly. A fast two-week-step ramp to 15 mg pushed about a quarter of participants off the drug for side effects. Slowing the ramp to the label cadence (2.5 mg start, 2.5 mg steps, four-week holds) dropped that to mid-single digits at every maintenance dose, at no cost to the 12-week result, and the dedicated slow-titration trial reached placebo range.¹⁰ Reaching 15 mg is not the problem. Reaching it fast is.

The cross-phase result puts a number on that difference. With little or no escalation, the tirzepatide dose associated with nausea in half the exposed population was 15.6 mg per week; under the full regimen it was 78.7 mg per week, a 5.04-fold shift. Vomiting moved 4.83-fold. The confidence intervals did not overlap. Across nine incretin drugs, tolerance tracked escalation duration and step count, while the starting dose as a fraction of maintenance did not.¹⁰

The four-week hold is not arbitrary. Three clocks converge on it. Blood levels take about four weeks to settle after a step.⁸ The stomach-slowing effect that drives early nausea builds and then adapts over roughly the same window.⁹ And gut symptoms cluster at the first dose and at each increase, then ease with time on a held dose.¹⁰ The label waits for the last step to settle before adding the next.

That same stomach-slowing window is why oral birth control needs backup. After starting and after each dose increase, tirzepatide can cut the peak absorption of an oral contraceptive by more than half, so the label guidance is a non-oral method or added barrier protection for four weeks after starting and four weeks after each increase.⁹ ²² It is a first-dose-and-escalation effect, not a permanent block on all oral drugs.

Some phenotypes plausibly need a slower-than-label climb: lighter bodies (higher exposure per milligram), a history of severe GLP-1 gut intolerance, a high baseline heart rate, or a lean, low-reserve build. Slow titration lowers the acute burden; it cannot make a high dose appropriate for a low-substrate body, remove the heart-rate tail in a sensitive person, or guarantee anyone reaches 15 mg in real life.

## Microdosing Tirzepatide

A tirzepatide microdose is best defined as below the 2.5 mg starter, usually 0.5, 1.0, 1.5, or 2.0 mg weekly. The 2.5 mg dose is better called the low-dose starter, because it is the labeled start and now has short direct non-diabetic data behind it.¹⁸

Microdosing has been used for tolerability testing, metabolic-marker support, step-down protocols, and maintenance, not for proven long-term obesity outcomes. Evidence weakens as the dose falls.

A 26-week diabetes study measured human activity at 1 mg, but its endpoint was blood sugar rather than long-term weight.²¹ A short outpatient cohort measured about 4.7% weight loss over four weeks at 2.5 mg.¹⁸ Below 1 mg, estimates rely on pharmacokinetics and mechanism.

| Weekly dose | Evidence anchor | What can be said |
| --- | --- | --- |
| 0.5 mg | Extrapolated | Plausible low-signal experiment; no measured obesity outcome |
| 1.0 mg | 26-week diabetes dose-ranging arm.²¹ | Human activity exists; the endpoint was glycemic |
| 1.5–2.0 mg | Interpolation from the 1 mg and 2.5 mg anchors | Plausible metabolic band; outcomes are projections |
| 2.5 mg | Label starter plus short non-diabetic cohort.¹⁸ | Direct short signal; not long-duration RCT proof |

Pen-based Mounjaro and Zepbound products do not dose below 2.5 mg. Sub-2.5 mg dosing depends on product format, clinician supervision, and current compounding rules. For vial-based microdosing, concentration matters more than vial size. A 10 mg vial in 2 mL of bacteriostatic water gives 5 mg/mL, where a 1 mg dose draws 0.2 mL (20 units on a U-100 syringe) and a 0.5 mg dose draws 0.1 mL (10 units). Smaller draws demand steadier technique.

## Tirzepatide Maintenance Dose After Weight Loss

The clearest maintenance band is 5–10 mg weekly, based on the obesity dose-response curve and real-world prescribing.¹ ¹⁸ A 2.5 mg track has short direct data and real-world support for stable maintainers, but no long-duration maintenance trial.¹⁸

Continuing tirzepatide holds weight far better than stopping. After about 21% initial loss, participants who continued lost another 5.5%; those switched to placebo regained about 14% over the next year.¹²

Weight loss slows toward a plateau on a held dose rather than continuing indefinitely. Higher doses reached that plateau later in the trial.¹²

In a 112-week step-down trial, participants maintained 21.9% loss on the top dose, 16.6% after stepping down to 5 mg, and 9.9% on placebo. Rescue therapy was needed by 8%, 25%, and 67%, respectively.¹² Five milligrams preserved most, but not all, of the benefit of continuing the effective dose.

| Maintenance path | Dose | Good fit |
| --- | --- | --- |
| Continue effective dose | 10–15 mg weekly | Still losing, still obese-range, or hunger returns fast |
| Step down | 7.5–10 mg weekly | Goal reached, but 5 mg feels too light |
| Standard maintenance | 5 mg weekly | Stable appetite, waist, and labs |
| Lower-dose maintenance | 2.5 mg weekly | Stable maintainer with a strong food and training base |
| Extended interval | 2.5–5 mg every 10–14 days | Evidence-light; hunger drifts in the back half of the interval |

Step-down frameworks hold each lower dose for 8 to 12 weeks. Rising hunger, waist growth, weight gain above about 2 lb per month, persistent heart-rate elevation, or declining strength indicate that the lower dose is not maintaining the prior response.

## Coming Off Tirzepatide

Stopping brings appetite and weight-regain pressure back, and that regain is the default, not a willpower failure. It is class-wide counter-regulation: stopping removes the signal that was holding down a set-point the body still defends.¹² The felt marker of the rebound is the return of food noise, which patients in the exit interviews reported as the first sign the loss was reversing.¹²

Metabolic loss tracks weight regain. In the withdrawal cohort, regaining half of the lost weight raised insulin resistance by roughly 35% to 40%, and blood pressure rose as weight returned.¹²

Taper frameworks combine at least 1.2 g/kg of protein with resistance training before the drug signal fades. Restart timing remains unsettled because trials have not measured re-titration after a prolonged stop.

## Side Effects and Safety

Gastrointestinal, heart-rate, and stomach-emptying effects are coupled to dose and escalation. Low blood sugar depends mainly on concurrent insulin or sulfonylurea use. Pancreatitis, gallbladder, thyroid, and kidney events were uncommon in the measured programs; each needs its own reading rather than one blanket safety conclusion.

Adverse-event tables capture what trial staff asked about or participants reported. In the protocol sections checked for this update, collection used a nonleading open question, and dietary counseling, antiemetics, dose interruption, or dose reduction could happen before the published rate was counted. The share receiving antiemetics was not published.

This wording has been verified in two trial protocols and one adverse-event definition section, not across the entire program. The rates below are volunteered, post-mitigation trial measurements rather than symptom-checklist incidence or a complete inventory of lived effects.

### Gastrointestinal effects: the main titration bottleneck

Nausea, diarrhea, constipation, and vomiting run around 40 to 44% overall, dose-dependent in how many people report them but mild-dominant in severity: severe events stay at or below about 1.7% in any category even at the top dose.⁸ In the obesity program the by-dose rates run nausea 25/29/28%, diarrhea 19/21/23%, and vomiting 8/11/13% at 5/10/15 mg.⁸

Nausea and diarrhea peak early in escalation. Vomiting can peak later near the upper steps; in a 15 mg diabetes trial arm it was highest during weeks 12–16 rather than weeks 0–4. All three settle to a lower, nonzero plateau after escalation.

### Heart rate: the escalation transient

This is the two-instruments effect covered above: a modest chronic mean, a larger escalation peak, and a lean, East-Asian tail.¹¹ Blood pressure moves the other way, down about 6 to 9 mmHg systolic, so the heart-rate rise is not a blood-pressure effect, and it reverses when the drug stops.²⁰

### Low blood sugar tracks the insulin background

On its own tirzepatide is insulin-sparing and rarely causes low blood sugar. Stacked on top of insulin or a sulfonylurea it can, and the lever is de-intensifying that background drug, not lowering the tirzepatide dose.¹³

### Over-loss in low-BMI deep responders

Across the obesity trials, about 7% of participants fell below a BMI of 22, some by week 12. The share approached 15% by week 88 in the longest trial, while clinical underweight remained below 0.5%.¹⁶

The signal clustered in lower-baseline deep responders. Micronutrient status was not measured systematically, so low reported rates of nutrition events do not establish nutritional adequacy.

### Skin sensitivity: an emerging signal

Skin burning and abnormal touch sensitivity (dysesthesia) appears as a dose-related, reversible signal in two case series and post-market surveillance.¹⁹ Trials did not pre-specify it, and the tirzepatide label does not list it.

No treated-population incidence has been established. The published tirzepatide cases followed dose escalation and improved after dose reduction or discontinuation; one recurred when the trigger dose was retried.

### Class-level and rare concerns

Adjudicated pancreatitis ran about 0.2% without a measured dose gradient. Gallbladder events were uncommon but occurred more often with greater weight loss. The thyroid warning began with rodent C-cell tumors; human trials have not resolved a dose-linked signal, and personal or family medullary thyroid cancer or MEN2 remains a contraindication.

Reported acute kidney injury was chiefly linked to dehydration during severe gastrointestinal illness, but the trial tables cannot prove that every kidney event followed that path.⁸ ¹⁴ Anti-drug antibodies formed in roughly half to two-thirds of users; the measured program did not find an effect on clearance, weight, or blood sugar.²²

### Benefits that look like side effects

Tirzepatide lowers uric acid (about -0.7 to -1.0 mg/dL, mostly through weight loss) and lowers blood pressure. Both appear in adverse-event tables as preferred terms, but they are benefits, not harms.²⁰

## Split Dosing and Frequency

The trial and label schedule is once weekly. Splitting the same weekly total into two injections, often every 3 to 4 days, is a tolerability strategy used outside the formal schedule. A smaller per-injection peak may reduce nausea and heart-rate pressure during escalation, and a smaller trough may soften the late-week hunger some users report. The evidence is pharmacokinetic and practice-based, not controlled outcome evidence.

| Pattern | Example | Evidence boundary |
| --- | --- | --- |
| Weekly | 5 mg every 7 days | Trial and label schedule |
| Twice weekly | 2.5 mg every 3.5 days for a 5 mg weekly total | PK/practice strategy for peaks and troughs |
| Every 3 days | About 43% of the weekly total per injection | More frequent than label; a smoothing strategy |
| Every 10–14 days | 2.5–5 mg extended interval | Community maintenance practice; no controlled coverage |

Extended intervals are the weakest layer. With a roughly 5.4-day half-life, a biweekly schedule creates a real valley before the next shot. If hunger, waist, or weight drift shows up in the back half of the interval, weekly dosing better preserves the exposure floor.

## How to Reconstitute Lyophilized Tirzepatide

This section applies only to lyophilized vial products that require reconstitution. Approved U.S. tirzepatide pens, single-dose vials, multi-dose vials, and KwikPens are supplied as liquid and must not be reconstituted.

For a lyophilized product, use the diluent and beyond-use instructions supplied by the dispensing pharmacy or manufacturer; 4–6 weeks is not a universal storage rule. Wipe both stoppers with alcohol, add bacteriostatic water down the inside glass wall, and swirl until clear without shaking. The tables below show concentration math, not a claim about approved formats. For a visual walk-through, see the [reconstitution guide](/content/reconstitution).


### How much BAC water for a 10 mg vial of tirzepatide?

A 10 mg tirzepatide vial with 1 mL of bacteriostatic water makes 10 mg/mL, where 5 mg draws 50 units and 10 mg draws 100 units. The table gives the water for each dose.

| Dose | BAC Water | Concentration | Syringe Draw |
| --- | --- | --- | --- |
| 1 mg | 3 mL | 3.33 mg/mL | 0.3 mL / 30 units |
| 2 mg | 2.5 mL | 4 mg/mL | 0.5 mL / 50 units |
| 2.5 mg | 3 mL | 3.33 mg/mL | 0.75 mL / 75 units |
| 5 mg | 1 mL | 10 mg/mL | 0.5 mL / 50 units |
| 7.5 mg | 1 mL | 10 mg/mL | 0.75 mL / 75 units |
| 10 mg | 1 mL | 10 mg/mL | 1 mL / 100 units |

### How much BAC water for a 15 mg vial of tirzepatide?

A 15 mg tirzepatide vial with 1 mL of bacteriostatic water makes 15 mg/mL, where 7.5 mg draws 50 units and 15 mg draws 100 units. The table gives the water for each dose.

| Dose | BAC Water | Concentration | Syringe Draw |
| --- | --- | --- | --- |
| 1 mg | 3 mL | 5 mg/mL | 0.2 mL / 20 units |
| 2 mg | 2.3 mL | 6.52 mg/mL | 0.31 mL / 31 units |
| 2.5 mg | 3 mL | 5 mg/mL | 0.5 mL / 50 units |
| 5 mg | 3 mL | 5 mg/mL | 1 mL / 100 units |
| 7.5 mg | 1 mL | 15 mg/mL | 0.5 mL / 50 units |
| 10 mg | 1.2 mL | 12.5 mg/mL | 0.8 mL / 80 units |
| 12.5 mg | 1.2 mL | 12.5 mg/mL | 1 mL / 100 units |
| 15 mg | 1 mL | 15 mg/mL | 1 mL / 100 units |

### How much BAC water for a 20 mg vial of tirzepatide?

A 20 mg tirzepatide vial with 1 mL of bacteriostatic water makes 20 mg/mL, where 10 mg draws 50 units and 15 mg draws 75 units. The table gives the water for each dose.

| Dose | BAC Water | Concentration | Syringe Draw |
| --- | --- | --- | --- |
| 1 mg | 3 mL | 6.67 mg/mL | 0.15 mL / 15 units |
| 2 mg | 3 mL | 6.67 mg/mL | 0.3 mL / 30 units |
| 2.5 mg | 2.4 mL | 8.33 mg/mL | 0.3 mL / 30 units |
| 5 mg | 3 mL | 6.67 mg/mL | 0.75 mL / 75 units |
| 7.5 mg | 2.4 mL | 8.33 mg/mL | 0.9 mL / 90 units |
| 10 mg | 1 mL | 20 mg/mL | 0.5 mL / 50 units |
| 12.5 mg | 1.2 mL | 16.67 mg/mL | 0.75 mL / 75 units |
| 15 mg | 1 mL | 20 mg/mL | 0.75 mL / 75 units |

### How much BAC water for a 30 mg vial of tirzepatide?

A 30 mg tirzepatide vial with 3 mL of bacteriostatic water makes 10 mg/mL, where 5 mg draws 50 units and 10 mg draws 100 units. The table gives the water for each dose.

| Dose | BAC Water | Concentration | Syringe Draw |
| --- | --- | --- | --- |
| 2 mg | 3 mL | 10 mg/mL | 0.2 mL / 20 units |
| 2.5 mg | 3 mL | 10 mg/mL | 0.25 mL / 25 units |
| 5 mg | 3 mL | 10 mg/mL | 0.5 mL / 50 units |
| 7.5 mg | 3 mL | 10 mg/mL | 0.75 mL / 75 units |
| 10 mg | 3 mL | 10 mg/mL | 1 mL / 100 units |
| 12.5 mg | 2.4 mL | 12.5 mg/mL | 1 mL / 100 units |
| 15 mg | 1 mL | 30 mg/mL | 0.5 mL / 50 units |

### How much BAC water for a 60 mg vial of tirzepatide?

A 60 mg tirzepatide vial with 3 mL of bacteriostatic water makes 20 mg/mL, where 10 mg draws 50 units and 15 mg draws 75 units. The table gives the water for each dose.

| Dose | BAC Water | Concentration | Syringe Draw |
| --- | --- | --- | --- |
| 2.5 mg | 2.4 mL | 25 mg/mL | 0.1 mL / 10 units |
| 5 mg | 3 mL | 20 mg/mL | 0.25 mL / 25 units |
| 7.5 mg | 2.4 mL | 25 mg/mL | 0.3 mL / 30 units |
| 10 mg | 3 mL | 20 mg/mL | 0.5 mL / 50 units |
| 12.5 mg | 2.4 mL | 25 mg/mL | 0.5 mL / 50 units |
| 15 mg | 3 mL | 20 mg/mL | 0.75 mL / 75 units |

For sterile preparation technique, use the [Peptide Reconstitution Guide](/content/reconstitution). For tirzepatide mechanism, clinical outcomes, and safety evidence, see the [Tirzepatide clinical guide](/content/tirzepatide).

## FAQ

**Dosing basics**

### What is the starting dose of tirzepatide?

The labeled starting dose is 2.5 mg weekly for at least four weeks. It is the starter dose, not the obesity-trial floor. The first 72-week non-diabetic obesity dose is 5 mg weekly.¹ The lowest measured human trial dose is 1 mg weekly in type 2 diabetes.²¹

### Is 2.5 mg tirzepatide therapeutic?

It depends on the claim. The label treats 2.5 mg as the starting dose before 5 mg. A short non-diabetic cohort recorded weight and insulin-resistance movement during an initial 2.5 mg phase lasting 4.2 ± 0.7 weeks (about -4.7% body weight), followed by a longer 5 mg phase in the same participants.¹⁸ That makes "2.5 mg has no data" outdated. It does not make 2.5 mg a dose-isolated long-term maintenance trial or equal to the 5 mg obesity-trial floor.

### What weight-loss outcomes are observed with tirzepatide?

In the 72-week non-diabetic obesity trial, adults lost -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg.¹ Real-world outcomes vary because dose reached, adherence, and baseline state vary; broad real-world cohorts read lower than trial completers, and the gap is mostly persistence, not a different drug.¹⁸

### How do tirzepatide vial sizes compare for common dosing patterns?

Match the vial to the weekly dose and the 4–6 week use window. A 60 mg vial is economical at 10–15 mg weekly but too large for a 1–2 mg microdose that would sit for months. At 2.5–5 mg, a 10 or 20 mg vial better matches the use window.

**Reconstitution & Syringe Units**

### How many units is 2.5 mg of tirzepatide?

2.5 mg of tirzepatide is 25 units on a U-100 insulin syringe at the common 10 mg/mL concentration (a 10 mg vial in 1 mL of bacteriostatic water). At a more concentrated 20 mg/mL mix it is about 13 units.

### How many units is 5 mg of tirzepatide?

5 mg of tirzepatide is 50 units at the common 10 mg/mL concentration (a 10 mg vial in 1 mL of BAC water). At 20 mg/mL it is 25 units.

### How many units is 7.5 mg of tirzepatide?

7.5 mg of tirzepatide is 75 units at a concentration of 10 mg/mL. At a 20 mg/mL mix it is about 38 units.

### How many units is 10 mg of tirzepatide?

10 mg of tirzepatide is 100 units (a full 1 mL insulin syringe) at 10 mg/mL. Reconstitute at 20 mg/mL to bring the same dose down to 50 units.

### How many units is 15 mg of tirzepatide?

15 mg of tirzepatide is 150 units at 10 mg/mL, which is more than one 1 mL syringe. At 20 mg/mL it is 75 units in a single draw.

**Microdosing**

### What is a tirzepatide microdose?

A microdose is any weekly dose below the 2.5 mg label starter, usually 0.5–2 mg weekly. The 1 mg dose has direct human diabetes-trial activity.²¹ Below 1 mg is more speculative. The microdose case is best framed as metabolic or maintenance translation, not proven 72-week obesity dosing.

### Does microdosing tirzepatide work for weight loss?

It can, but the evidence is weaker than the label-dose weight-loss evidence. No 72-week obesity trial tested below 5 mg. Modeled 1–2 mg outcomes are projections. At 2.5 mg, a short outpatient cohort measured about -4.7% body weight over roughly four weeks.¹⁸

### How is draw volume calculated for a tirzepatide microdose?

Volume depends on concentration. A 10 mg vial in 2 mL of BAC water gives 5 mg/mL. A 1 mg dose draws 0.2 mL (20 units on a U-100 syringe), and a 0.5 mg dose draws 0.1 mL (10 units). The calculator handles other vial sizes and BAC volumes.

**Maintenance and stopping**

### What is the maintenance dose after weight loss?

The clearest maintenance band is 5–10 mg weekly. A 2.5 mg track has short direct data and real-world support for stable maintainers, but continuing tirzepatide has much stronger evidence than stopping.¹⁸ ¹² At week 112, stepping down to 5 mg preserved 16.6% weight loss versus 21.9% on the top dose and 9.9% on placebo.

### What evidence supports remaining at 2.5 mg of tirzepatide before dose escalation?

Short non-diabetic data support remaining at 2.5 mg when weight and insulin-resistance markers are already moving and tolerability favors a hold.¹⁸ The label still positions 2.5 mg as the starter before 5 mg, so it is a defensible low-dose floor for selected users rather than a replacement for the 5 mg obesity-trial floor.

### What happens after tirzepatide is discontinued?

Appetite and weight-regain pressure return. In the withdrawal trial, continuing preserved loss far better than switching to placebo, which regained about 14% over a year.¹² The metabolic benefit fades in proportion to the weight regained, so a taper plus protein and resistance training beats a hard stop.

### What weight changes are observed after stopping tirzepatide?

Weight regain is common after discontinuation. In the withdrawal trial, participants switched to placebo regained about 14% over the following year.¹² Tapering, at least 1.2 g/kg of protein, resistance training, and follow-up reduce the risk, but no post-stop protocol guarantees maintenance.

**Body composition, liver, and safety**

### Does tirzepatide preserve lean mass better than semaglutide?

The best non-diabetic body-composition anchor favors tirzepatide, about 75:25 fat-to-lean loss in its DXA data versus about 62:38 in semaglutide's.³ This is cross-trial evidence, not a head-to-head maintenance-dose DXA result. Protein and resistance training still matter.

### How much can tirzepatide reduce liver fat?

In a diabetes MRI substudy, liver fat fell up to 47% at 15 mg versus about 11% on insulin.⁶ In biopsy-confirmed fatty-liver disease with fibrosis, a large share of participants on 15 mg had disease resolution versus a small share on placebo.¹⁵ These are not microdose data.

### What are the most common side effects?

Gastrointestinal effects lead: nausea, diarrhea, constipation, and vomiting, dose-dependent and clustered during escalation, mostly mild.⁸ Tirzepatide also produces a modest chronic heart-rate rise with a larger escalation-phase peak.¹¹ Oral-contraceptive absorption can fall after starting and after each increase, so use backup or non-oral contraception for 4 weeks each time.⁹ ²²

### What is known about concurrent metformin and tirzepatide use?

Concurrent metformin use is well represented in diabetes trials, which often added tirzepatide on top of metformin. For non-diabetic users the question is whether both are needed: tirzepatide is far stronger for weight loss at 5 mg and above, while metformin is cheaper, oral, and more modest.

## Related Topics

- [Tirzepatide Deep Dive](/content/tirzepatide) — mechanism, clinical results, and comparison context
- [Retatrutide vs Tirzepatide](/content/retatrutide-vs-tirzepatide) — triple versus dual receptor comparison
- [Semaglutide vs Tirzepatide](/content/semaglutide-vs-tirzepatide) — direct comparison and evidence boundaries
- [GLP-1 Dosing Optimizer](/glp-1/dosing) — split-frequency modeling and plasma curves
- [Full Reconstitution Calculator](/tools/calculator) — all-peptide vial math and custom BAC volumes
- [GLP-1 Lean Mass Guide](/content/glp1-lean-mass) — protein, training, and body-composition evidence

## References

¹ Tirzepatide for non-diabetic obesity — SURMOUNT-1 randomized 2,539 adults to 5, 10, or 15 mg for 72 weeks. The page uses the treatment-regimen estimates, -15.0/-19.5/-20.9%, because they include discontinuation and rescue rather than describing only adherent completers. This is the reference body behind the dose ladder: mean BMI 38, no diabetes, lifestyle counseling in every arm. The trial supplies weight response and week-72 pulse; the pooled DXA partition comes from ref ³. [Jastreboff NEJM 2022](https://doi.org/10.1056/NEJMoa2206038).

² Tirzepatide versus semaglutide — SURMOUNT-5 is the direct 72-week instrument in non-diabetic obesity. Under the treatment-regimen estimand, tirzepatide reached -20.2% and semaglutide -13.7%. That is why the page uses it instead of subtracting two separate pivotal trials for weight. The trial was open-label and did not include DXA, so it does not carry the body-composition claim. [Aronne NEJM 2025](https://www.nejm.org/doi/full/10.1056/NEJMoa2416394).

³ Tirzepatide body composition — the SURMOUNT-1 DXA substudy partitions the mean lost mass at about 75% fat and 25% lean and records visceral-fat reduction near 40%. “Lean” is not synonymous with muscle: it includes water and organ mass. The page therefore uses the ratio as a composition anchor, not a claim that one quarter of loss is contractile tissue, and keeps muscle quality and over-loss in ref ¹⁶. [Look DOM 2025](https://doi.org/10.1111/dom.16275).

⁴ Tirzepatide in obesity plus T2D — SURMOUNT-2 produced -12.8% and -14.7% at 10 and 15 mg, about 6–7 percentage points below the matched doses in non-diabetic SURMOUNT-1. The page treats that gap as a cohort translation, not a weaker formulation: the diabetes instrument is glycemically loud and weight-attenuated. [Garvey Lancet 2023](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01200-X/fulltext).

⁵ Glycemic ceiling versus weight ceiling — SURPASS-2 randomized 5/10/15 mg tirzepatide against semaglutide 1 mg in T2D. Tirzepatide HbA1c changes were -2.01/-2.24/-2.30 percentage points: most of the glycemic effect was already present at 5–10 mg, while weight continued separating by dose. That divergence is why the page says the 15 mg justification is mainly additional weight loss rather than additional glucose lowering. [Frías NEJM 2021](https://www.nejm.org/doi/full/10.1056/NEJMoa2107519).

⁶ Liver-fat MRI — the SURPASS-3 substudy measured relative liver-fat reductions of -29.8/-39.6/-47.1% at 5/10/15 mg versus -11.2% on insulin degludec. This is a T2D cohort selected for a fatty-liver measurement, so the page uses it for direction and dose response in liver fat, not as a forecast for a lean liver with little baseline fat to lose. [Gastaldelli Lancet D&E 2022](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00070-5/fulltext).

⁷ Receptor architecture — Willard measures tirzepatide as GIPR-forward and GLP-1R-biased: full cAMP signaling with reduced GLP-1R beta-arrestin recruitment, not simply “two full native hormones in one molecule.” The occupancy chart combines those functional-potency values with free exposure using albumin Kd 1.86 μM and free fraction 0.29%. GCGR EC50 329 nM is the negative control that keeps tirzepatide out of the glucagon-agonist lane. Occupancy is a model of free-drug engagement, not a measured human receptor scan. [Willard JCI Insight 2020](https://insight.jci.org/articles/view/140532); [Coskun Mol Metab 2018](https://doi.org/10.1016/j.molmet.2018.09.009).

⁸ Tirzepatide PK and adverse-event ascertainment — **Level versus shape:** Schneck pooled 39,644 samples from 5,802 people across 19 studies. Its post-hoc CL/F 0.061 L/h gives a 5.4-day half-life and about 1.7× accumulation; MHRA Phase 3 average concentrations, 491 and 1,470 ng/mL at 5 and 15 mg, independently support that value for exposure level. The structural model’s ka 0.0373/h, Q 0.126 L/h, V1 2.47 L, and V2 3.98 L are used for curve shape. Structural and post-hoc CL/F differ by 33%, so the page does not force one parameter set to do both jobs. **Body-weight inheritance:** Schneck fixed the clearance exponent at BW^0.8 rather than estimating it and cited Wang & Prueksaritanont 2010, a generic therapeutic-protein scaling paper. Lilly’s later MAA model retained the prior structure and FDA restated it; the 70/90/120 kg exposure ratios inherit that choice. The 70 kg estimates agree (+22% to +23% versus 90 kg), while the 120 kg estimates do not (-21% FDA, -33% Schneck, -22.4% from the digitized FDA figure). The page reports the disagreement rather than laundering 0.8 into a tirzepatide-measured constant. [Schneck CPT:PSP 2024](https://doi.org/10.1002/psp4.13099); [Wang & Prueksaritanont 2010](https://doi.org/10.1002/bdd.708); FDA Mounjaro NDA 215866 and Zepbound NDA 217806 reviews. **Injection and GI collection:** abdomen, thigh, and upper arm produced similar exposure. In the checked protocol sections, adverse events were volunteered after a nonleading open question and could be preceded by diet counseling, antiemetics, interruption, or dose reduction; antiemetic use was not published. That collection wording is verified in SURMOUNT-3 §§6.6.2/8.3.2.11, SURMOUNT-CN §7.4.2, and GPIF §8.3.1.1, not assumed for every trial.

⁹ Tirzepatide gastric emptying and the oral-drug interaction — GLP-1R-mediated delay at 4.5–5 mg with tachyphylaxis over about 4 weeks of repeat dosing and re-engagement on escalation, measured by acetaminophen absorption: [Urva DOM 2020](https://doi.org/10.1111/dom.14060). The oral-contraceptive interaction is a separate study (GPGR), reported in the FDA Mounjaro NDA 215866 summary review: a single 5 mg tirzepatide dose with a combination oral contraceptive (0.035 mg ethinyl estradiol / 0.25 mg norgestimate) reduced the **Cmax of norelgestromin and ethinyl estradiol by 55% to 59%** — a range spanning both analytes, not a separate figure for each — with AUC lowered 28.8% (norelgestromin) and 27% (ethinyl estradiol), and tmax delayed 2.5 to 4.5 hours. Note the analyte is norelgestromin, the active metabolite, not norgestimate the parent. Lilly argued the Cmax reduction was of limited clinical relevance because AUC drives contraceptive efficacy; FDA's Clinical Pharmacology team disagreed, concluding the reductions "could pose a clinically significant risk of loss of efficacy of contraception and unintended pregnancy" — which is the basis for the backup-contraception guidance in ref ²².

¹⁰ Titration governs tolerability — fast 2-week ramp to 15 mg gave 24.5% AE-discontinuation (Frias 2018); slow 8-week regimens brought it to 0-3.8%, near placebo, at no efficacy cost (Frias 2020). Cross-phase ED50 analysis found a 5.04x nausea-tolerance shift and 4.83x vomiting shift under the full tirzepatide ladder; across nine incretin drugs, escalation duration and step count tracked tolerance while starting fraction did not (Nauck 2026): [Frias Lancet 2018](https://doi.org/10.1016/S0140-6736(18)32260-8); [Frias DOM 2020](https://doi.org/10.1111/dom.14009); [Nauck DOM 2026](https://doi.org/10.1111/dom.70613).

¹¹ Heart-rate escalation peak vs steady-state mean — SURMOUNT-1 week-72 pulse +0.6/+2.3/+2.6 bpm; FDA Zepbound Medical Review (Soccio) escalation peak at weeks 16-20 +2.8/+5.1/+4.1 bpm, change over 20 bpm in about 10% of tirz vs 3.35% placebo, Japanese 15 mg abnormal-pulse 23.3% vs 7.1%; Furihata lean Japanese Phase 1 +10 to +13 bpm during escalation: FDA Zepbound NDA 217806 Medical Review; [Furihata DOM 2022](https://doi.org/10.1111/dom.14634).

¹² Maintenance and discontinuation — SURMOUNT-4, continue vs placebo switch after lead-in to about 20.9% loss: stopping regained about +14% over 52 weeks while continuing lost a further -5.5%; HOMA2-IR returns in proportion to regain (about +0.6% at under-25% regain to +39.5% at 50-75%); time-to-plateau lengthens with dose. SURMOUNT-MAINTAIN (Horn 2026, 112 weeks): continued top dose -21.9% vs 5 mg step-down -16.6% vs placebo -9.9%, rescue therapy 8/25/67%: [Aronne JAMA 2024](https://jamanetwork.com/journals/jama/fullarticle/2825688); [Horn Lancet 2026](https://doi.org/10.1016/S0140-6736(26)00656-2); [NCT06047548](https://clinicaltrials.gov/study/NCT06047548).

¹³ Glycemic mechanism and insulin sparing — sensitization not secretion: fasting insulin and C-peptide fall while insulin sensitivity (HOMA2-%S) rises +31.8/+43.2/+49.9% (SURPASS J-mono, Hamamoto 2025); basal insulin cut from 47 to 8-20 IU replacing basal-bolus (SURPASS-6); hypoglycemia tracks the insulin background not tirzepatide dose (SURPASS-5): [Dahl JAMA 2022](https://jamanetwork.com/journals/jama/fullarticle/2790144); [Rosenstock JAMA 2023](https://jamanetwork.com/journals/jama/fullarticle/2807271); Hamamoto Diabetes Ther 2025.

¹⁴ Kidney and cardiovascular outcomes — SURPASS-4 kidney composite HR 0.58, slower eGFR decline (-1.4 vs -3.6 mL/min/1.73m2/yr), UACR -6.8% vs +36.9%; SURPASS-CVOT (N=13,165, median 4 years) was noninferior on 3-point MACE (HR 0.92; superiority not met). The MACE-4 HR 0.88 and all-cause death HR 0.84 intervals were nominal because the multiplicity-controlled sequence stopped at the failed primary superiority test; 62 of the 103 fewer deaths were non-cardiovascular: [Heerspink SURPASS-4 kidney post-hoc](https://doi.org/10.1016/S2213-8587(22)00243-1); [Nicholls NEJM 2025](https://doi.org/10.1056/NEJMoa2505928).

¹⁵ Tirzepatide for MASH with fibrosis — SYNERGY-NASH directly measured histology after 52 weeks in biopsy-confirmed MASH with stage F2–F3 fibrosis. At 15 mg, MASH resolution without worsening fibrosis occurred in 62% versus 10% on placebo. The page uses this as a disease-resolution instrument in an already diseased liver, not as microdose evidence or a general liver-health percentage. [Loomba NEJM 2024](https://pubmed.ncbi.nlm.nih.gov/38856224/).

¹⁶ Over-loss and muscle — the pooled SURMOUNT analysis shows the tail changing with time: BMI below 22 reached about 8.3% by week 72 and 14.6% in the longer 88-week SURMOUNT-4 instrument, while BMI below 18.5 remained uncommon, roughly 0.3–1.5%. That locates the issue in deep, long responders rather than the cohort mean. [Almandoz Obesity Pillars 2026](https://doi.org/10.1016/j.obpill.2026.100248). MRI data show muscle volume falling about as body size predicts while muscle quality improves beyond that estimate, so volume loss alone is not functional loss. [Sattar Lancet Diabetes & Endocrinology 2025](https://doi.org/10.1016/S2213-8587(25)00027-0). The lean-adjacent n=1 recovery after resistance work and higher protein is a case-level warning, not a rate estimate.

¹⁷ Appetite and food reward — Martin’s six-week, three-arm Phase 1 measured ad-libitum lunch intake, craving, hedonic hunger, restraint, impulsiveness, and food-cue fMRI against liraglutide 3.0 mg and placebo. Tirzepatide reduced measured lunch intake by 524.6 kcal versus placebo at week 3; by week 6, intake was 657.8 kcal, or 72.4%, below its own baseline. Craving and hedonic-hunger measures moved while Barratt impulsiveness and volitional restraint did not. That is why the page describes lower drive to eat rather than stronger willpower. The behavioral instrument is stronger than the small, non-uniform imaging read. [Martin Nature Medicine 2025](https://doi.org/10.1038/s41591-025-03774-9).

¹⁸ Real-world dosing and outcomes — the spread is mostly a denominator and achieved-dose story: six-month persisters lose about 12–13% ([Hankosky](https://doi.org/10.1111/dom.16290)), a broad cohort about 9.8% ([Adamidis](https://doi.org/10.7759/cureus.107081)), and selected telehealth completers near 23% ([Duncan](https://doi.org/10.1016/j.obpill.2025.100236)). Those are different slices, not conflicting potencies. Mody shows 5 mg is often the modal maximum and many users remain below 10 mg by the sixth fill. [Mody](https://doi.org/10.1007/s13300-024-01684-6). Barrea’s sequential cohort supplies the short 2.5 mg anchor, about -4.7% during a 4.2-week initial phase, then -12.7% by the end of the longer 5 mg phase; because the same people advanced, it does not isolate long-term 2.5 mg maintenance. [Barrea](https://doi.org/10.17179/excli2025-9067).

¹⁹ Cutaneous dysesthesia/allodynia — published tirzepatide cases are dose-escalation-linked, resolve on dechallenge, and in one case recur at the trigger dose; Naranjo scoring was “probable.” FAERS supplies a reporting signal, while the active-comparator cohort signal comes from related GLP-1 agents rather than tirzepatide itself. The event is not on the tirzepatide label and no treated-population incidence is available. The page therefore names a reversible emerging reaction without assigning it a frequency or importing another drug’s rate. Ahern *Cureus* 2025; Chakrabarti/Campbell *Am J Case Rep* 2026; Chen *Sci Rep* 2025; Frey medRxiv 2026 preprint.

²⁰ Uric acid and blood pressure — SURMOUNT-1 uric acid fell -0.69/-0.92/-0.95 mg/dL across 5/10/15 mg; mediation analysis attributes 72.7% of the change to weight loss, leaving roughly 27% not explained by weight. That decomposition is why the page does not call the entire effect direct pharmacology or dismiss it as only weight. [Sattar 2026](https://doi.org/10.1016/j.ard.2025.10.009). Systolic pressure fell about 6–9 mmHg in the obesity program and moved back with withdrawal, tying much of that benefit to the maintained weight state.

²¹ Lowest direct dose anchor — Frías 2018 randomized 1, 5, 10, and 15 mg tirzepatide over 26 weeks in T2D. The 1 mg arm is the lowest registered human dose with measured glycemic activity. It supports “pharmacologically active below 2.5 mg”; it does not supply a 72-week obesity weight-loss estimate, and doses below 1 mg remain extrapolated. [Frías Lancet 2018](https://doi.org/10.1016/S0140-6736(18)32260-8).

²² Oral contraception and immunogenicity — FDA’s contraceptive instruction follows the first-dose gastric-emptying instrument in ref ⁹: use non-oral contraception or add a barrier method for four weeks after initiation and after every dose escalation. In the chronic-weight-management program, 64.5% (1,591/2,467) developed treatment-emergent anti-drug antibodies, but antibody status and titer did not measurably change PK, weight loss, or HbA1c. The positivity threshold was assay- and cohort-dependent, so the page does not rank that percentage against diabetes-program rates. FDA Mounjaro NDA 215866 label/Summary Review; FDA Zepbound NDA 217806 Summary, clinical-pharmacology, and immunogenicity reviews.

²³ Real-world patient-language layer — recurring themes and vocabulary drawn from the tirzepatide Reddit communities (r/Zepbound, r/Mounjaro, r/tirzepatide and related), read for theme prominence and the words users use, not for incidence. Among users who post about side effects, the most-discussed run nausea, fatigue, GI-other, anxiety, diarrhea, constipation, menstrual changes, and reflux/burps, in that order; "food noise" is the near-universal term for the appetite change. This is a signal-discovery instrument: proportions are among side-effect-disclosing posters rather than population rates, and symptom posts are structurally under-represented against progress posts, so it supports vocabulary and theme prominence, not magnitude. PeptideFox tirzepatide real-world evidence corpus.